{"id":18317,"date":"2025-07-25T10:13:16","date_gmt":"2025-07-25T10:13:16","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=18317"},"modified":"2025-07-25T10:13:16","modified_gmt":"2025-07-25T10:13:16","slug":"medicinova-shares-update-on-als-triglyceride-trials","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","title":{"rendered":"\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u3001ALS\u3068\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u8a66\u9a13\u306e\u6700\u65b0\u60c5\u5831\u3092\u767a\u8868"},"content":{"rendered":"

\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u306f\u3001\u30ca\u30b9\u30c0\u30c3\u30af\u30fb\u30b0\u30ed\u30fc\u30d0\u30eb\u30fb\u30de\u30fc\u30b1\u30c3\u30c8\u304a\u3088\u3073\u7c73\u56fd\u9023\u90a6\u8a3c\u5238\u53d6\u5f15\u6240\uff08NASDAQ\uff09\u3067\u53d6\u5f15\u3055\u308c\u3066\u3044\u308b\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f1a\u793e\u3067\u3059\u3002 \u6771\u4eac\u8a3c\u5238\u53d6\u5f15\u6240\u30b9\u30bf\u30f3\u30c0\u30fc\u30c9\u5e02\u5834<\/a>\u5f53\u793e\u306e\u958b\u767a\u5316\u5408\u7269\u3067\u3042\u308bMN-166\uff08\u30a4\u30d6\u30b8\u30e9\u30b9\u30c8\uff09\u304a\u3088\u3073MN-001\uff08\u30c1\u30da\u30eb\u30ab\u30b9\u30c8\uff09\u306b\u95a2\u3057\u3001\u73fe\u5728\u9032\u884c\u4e2d\u306e2\u3064\u306e\u91cd\u8981\u306a\u81e8\u5e8a\u8a66\u9a13\u306e\u767b\u9332\u306b\u95a2\u3059\u308b\u6700\u65b0\u60c5\u5831\u3092\u63d0\u4f9b\u3057\u307e\u3059\u3002<\/p>\n

\u5177\u4f53\u7684\u306b\u306f\u3001\u73fe\u5728\u9032\u884c\u4e2d\u306e\u30d5\u30a7\u30fc\u30ba2\/3\u8a66\u9a13\u3067\u3042\u308b COMBAT-ALS \u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u7121\u4f5c\u70ba\u5316\u304c\u5fc5\u8981\u306a\u88ab\u9a13\u8005\u6570\u304c\u4e00\u6841\u306b\u306a\u308a\u307e\u3057\u305f\u3002\u540c\u6642\u306b\u30012\u578b\u7cd6\u5c3f\u75c5\u306b\u3088\u308b\u8102\u8cea\u7570\u5e38\u75c7\u304a\u3088\u3073\u8102\u80aa\u6027\u809d\u75be\u60a3\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30d5\u30a7\u30fc\u30ba2\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u6700\u5f8c\u306e\u7121\u4f5c\u70ba\u5316\u88ab\u9a13\u80052\u540d\u3092\u52df\u96c6\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n

MN-166\uff08\u30a4\u30d6\u30b8\u30e9\u30b9\u30c8\uff09\u306b\u3064\u3044\u3066<\/h4>\n

MN-166\uff08\u30a4\u30d6\u30b8\u30e9\u30b9\u30c8\uff09\u306f\u3001\u30db\u30b9\u30db\u30b8\u30a8\u30b9\u30c6\u30e9\u30fc\u30bc4\u578b\uff08PDE4\uff09\u3068\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u904a\u8d70\u963b\u6b62\u56e0\u5b50\uff08MIF\uff09\u3092\u542b\u3080\u708e\u75c7\u6027\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u3092\u963b\u5bb3\u3059\u308b\u7d4c\u53e3\u6295\u4e0e\u53ef\u80fd\u306a\u4f4e\u5206\u5b50\u5316\u5408\u7269\u3067\u3059\u3002\u7b4b\u840e\u7e2e\u6027\u5074\u7d22\u786c\u5316\u75c7\uff08ALS\uff09\u3001\u9032\u884c\u6027\u591a\u767a\u6027\u786c\u5316\u75c7\uff08MS\uff09\u3001\u5909\u6027\u6027\u981a\u9ac4\u75c7\uff08DCM\uff09\u306a\u3069\u306e\u795e\u7d4c\u5909\u6027\u75be\u60a3\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u5f8c\u671f\u81e8\u5e8a\u958b\u767a\u6bb5\u968e\u306b\u3042\u308a\u3001\u81a0\u82bd\u816b\u3001\u30ed\u30f3\u30b0COVID\u3001\u5316\u5b66\u7642\u6cd5\u8a98\u767a\u6027\u672b\u68a2\u795e\u7d4c\u969c\u5bb3\uff08CIPN\uff09\u3001\u85ac\u7269\u4f7f\u7528\u969c\u5bb3\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3082\u958b\u767a\u4e2d\u3067\u3059\u3002\u3055\u3089\u306b\u3001MN-166\u306f\u3001\u6025\u6027\u547c\u5438\u7aae\u8feb\u75c7\u5019\u7fa4\uff08ARDS\uff09\u3092\u767a\u75c7\u3059\u308b\u30ea\u30b9\u30af\u306e\u3042\u308b\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u8a55\u4fa1\u3055\u308c\u307e\u3057\u305f\u3002 \u30e1\u30c7\u30a3\u30c1\u30ce\u30f4\u30a1<\/a> MN-166\u3001ALS\u6cbb\u7642\u85ac\u3068\u3057\u3066\u7c73\u56fdFDA\u304a\u3088\u3073\u6b27\u5ddeEMA\u3088\u308a\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d6\u5f97MN-166\u306f\u3001ALS\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066FDA\u3088\u308a\u30d5\u30a1\u30b9\u30c8\u30fb\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001MN-166\u306f\u81a0\u82bd\u816b\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306b\u6307\u5b9a\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a \u30ad\u30e5\u30e9\u30fc\u30ba\u3068\u30a2\u30eb\u30d5\u30a1\u30fb\u30d5\u30e5\u30fc\u30b8\u30e7\u30f3\u793e\u3001\u30a2\u30b9\u30bf\u30c1\u30f3-211\u306e\u5171\u540c\u7814\u7a76\u3092\u63a8\u9032<\/a><\/h4>\n

MN-001\uff08\u30c1\u30da\u30eb\u30ab\u30b9\u30c8\uff09\u306b\u3064\u3044\u3066<\/h4>\n

MN-001\uff08\u4e00\u822c\u540d\uff1a\u30c1\u30da\u30eb\u30ab\u30b9\u30c8\uff09\u306f\u3001\u7d4c\u53e3\u6295\u4e0e\u304c\u53ef\u80fd\u306a\u65b0\u898f\u306e\u4f4e\u5206\u5b50\u5316\u5408\u7269\u3067\u3042\u308a\u3001\u524d\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u3001\u30ed\u30a4\u30b3\u30c8\u30ea\u30a8\u30f3\uff08LT\uff09\u53d7\u5bb9\u4f53\u62ee\u6297\u4f5c\u7528\u3001\u30db\u30b9\u30db\u30b8\u30a8\u30b9\u30c6\u30e9\u30fc\u30bc\uff08PDE\uff09\uff08\u4e3b\u306b3\u304a\u3088\u30734\uff09\u963b\u5bb3\u4f5c\u7528\u30015-\u30ea\u30dd\u30ad\u30b7\u30b2\u30ca\u30fc\u30bc\uff085-LO\uff09\u963b\u5bb3\u4f5c\u7528\u306a\u3069\u3001\u8907\u6570\u306e\u6a5f\u5e8f\u306b\u3088\u308a\u6297\u708e\u75c7\u4f5c\u7528\u304a\u3088\u3073\u6297\u7dda\u7dad\u5316\u4f5c\u7528\u3092\u793a\u3059\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u30025-LO\/LT\u7d4c\u8def\u306f\u3001\u7dda\u7dad\u75c7\u767a\u75c7\u306e\u75c5\u539f\u56e0\u5b50\u3068\u3057\u3066\u4eee\u5b9a\u3055\u308c\u3066\u304a\u308a\u3001MN-001\u306e5-LO\u304a\u3088\u30735-LO\/LT\u7d4c\u8def\u306b\u5bfe\u3059\u308b\u963b\u5bb3\u4f5c\u7528\u306f\u3001\u7dda\u7dad\u75c7\u3092\u6cbb\u7642\u3059\u308b\u305f\u3081\u306e\u65b0\u3057\u3044\u30a2\u30d7\u30ed\u30fc\u30c1\u3067\u3059\u3002MN-001\u306f\u3001LOXL2\u30011\u578b\u30b3\u30e9\u30fc\u30b2\u30f3\u3001TIMP-1\u306a\u3069\u306e\u7dda\u7dad\u5316\u3092\u4fc3\u9032\u3059\u308b\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001MN-001\u306f\u3001CCR2\u3084MCP-1\u306a\u3069\u306e\u708e\u75c7\u3092\u4fc3\u9032\u3059\u308b\u907a\u4f1d\u5b50\u306e\u767a\u73fe\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u3053\u3068\u3082\u793a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3055\u3089\u306b\u3001MN-001\u306f\u3001\u30a2\u30e9\u30ad\u30c9\u30f3\u9178\u306e\u53d6\u308a\u8fbc\u307f\u3092\u963b\u5bb3\u3059\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u809d\u7d30\u80de\u306b\u304a\u3051\u308b\u30c8\u30ea\u30b0\u30ea\u30bb\u30ea\u30c9\u306e\u5408\u6210\u3092\u963b\u5bb3\u3059\u308b\u3053\u3068\u304c\u308f\u304b\u308a\u307e\u3057\u305f\u3002<\/p>\n

\u30bd\u30fc\u30b9 \u30b0\u30ed\u30fc\u30d6\u30cb\u30e5\u30fc\u30b9\u30ef\u30a4\u30e4\u30fc<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange, provides an update on the enrollment of two key ongoing clinical trials for the Company\u2019s developmental compounds MN-166 (ibudilast) and MN-001 (tipelukast), each of which is poised to complete randomization. Specifically, the Company is now down to single digit required randomization in its ongoing Phase 2\/3 COMBAT-ALS trial. Concurrently, the Company is seeking the final two randomized subjects for its Phase 2 trial in patients with dyslipidemia and fatty liver disease due to type 2 diabetes. About MN-166 (ibudilast) MN-166 (ibudilast) is an orally available small molecule compound that inhibits […]<\/p>\n","protected":false},"author":4,"featured_media":18318,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,89,211,237,182,206],"tags":[6546,6547,6545,6548,424,6544],"ppma_author":[205],"class_list":{"0":"post-18317","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-apac","8":"category-health-tech","9":"category-japan","10":"category-news","11":"category-pharma","12":"category-regional","13":"tag-clinical-trial","14":"tag-hypertriglyceridemia","15":"tag-ibudilast","16":"tag-medicinova","17":"tag-pharma","18":"tag-tipelukast"},"yoast_head":"\nMediciNova Reports Progress on ALS and Lipid Trials<\/title>\n<meta name=\"description\" content=\"MediciNova shares enrollment progress for trials of MN-166 and MN-001, with both studies nearing completion of the randomization phase.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MediciNova Reports Progress on ALS and Lipid Trials\" \/>\n<meta property=\"og:description\" content=\"MediciNova shares enrollment progress for trials of MN-166 and MN-001, with both studies nearing completion of the randomization phase.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-25T10:13:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u3001ALS\u3068\u8102\u8cea\u306e\u81e8\u5e8a\u8a66\u9a13\u306e\u9032\u6357\u3092\u5831\u544a","description":"MediciNova\u793e\u306f\u3001MN-166\u3068MN-001\u306e\u8a66\u9a13\u306e\u767b\u9332\u9032\u6357\u72b6\u6cc1\u3092\u5171\u6709\u3057\u3001\u4e21\u8a66\u9a13\u3068\u3082\u7121\u4f5c\u70ba\u5316\u6bb5\u968e\u306e\u5b8c\u4e86\u306b\u8fd1\u3065\u3044\u3066\u3044\u307e\u3059\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","og_locale":"ja_JP","og_type":"article","og_title":"MediciNova Reports Progress on ALS and Lipid Trials","og_description":"MediciNova shares enrollment progress for trials of MN-166 and MN-001, with both studies nearing completion of the randomization phase.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","og_site_name":"itbusinesstoday","article_published_time":"2025-07-25T10:13:16+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"MediciNova Shares Update on ALS, Triglyceride Trials","datePublished":"2025-07-25T10:13:16+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/"},"wordCount":370,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","keywords":["clinical trial","Hypertriglyceridemia","ibudilast","MediciNova","Pharma","tipelukast"],"articleSection":["APAC","Health Tech","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/","name":"\u30e1\u30c7\u30a3\u30b7\u30ce\u30d0\u793e\u3001ALS\u3068\u8102\u8cea\u306e\u81e8\u5e8a\u8a66\u9a13\u306e\u9032\u6357\u3092\u5831\u544a","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","datePublished":"2025-07-25T10:13:16+00:00","description":"MediciNova\u793e\u306f\u3001MN-166\u3068MN-001\u306e\u8a66\u9a13\u306e\u767b\u9332\u9032\u6357\u72b6\u6cc1\u3092\u5171\u6709\u3057\u3001\u4e21\u8a66\u9a13\u3068\u3082\u7121\u4f5c\u70ba\u5316\u6bb5\u968e\u306e\u5b8c\u4e86\u306b\u8fd1\u3065\u3044\u3066\u3044\u307e\u3059\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/07\/MediciNova-Provides-Enrollment-Update-for-Ongoing-ALS-and-Hypertriglyceridemia-Clinical-Trials.webp","width":1200,"height":800,"caption":"MediciNova"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/medicinova-shares-update-on-als-triglyceride-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"MediciNova Shares Update on ALS, Triglyceride Trials"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=18317"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18317\/revisions"}],"predecessor-version":[{"id":18319,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/18317\/revisions\/18319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/18318"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=18317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=18317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=18317"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=18317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}